Healthcare provider profile · identity verified

Arthur E. Apolinario, MD

Allopathic & Osteopathic Physicians|Family Medicine · CLINTON, NC · NPI 1679589055

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Arthur E. Apolinario, MD received $60.26 in general payments during 2025 across 3 reported records.

Abbott Laboratories accounted for 41.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$60.26

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Abbott Laboratories	Unresolved — no canonical attribution shown	$24.97	41.4%	1	2025
Esperion Therapeutics, Inc.	Unresolved — no canonical attribution shown	$22.18	36.8%	1	2025
Phathom Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$13.11	21.8%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$60.26	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FREESTYLE LIBRE 3 Normalized: freestyle libre 3	Device	Abbott Laboratories	$24.97	1	2025
Source payment records 2025-07-25 · Abbott Laboratories · $24.97 · Open Payments source
NEXLETOL Normalized: nexletol	Drug	Esperion Therapeutics, Inc.	$22.18	1	2025
Source payment records 2025-04-07 · Esperion Therapeutics, Inc. · $22.18 · Open Payments source
VOQUEZNA Normalized: voquezna	Drug	Phathom Pharmaceuticals, Inc.	$13.11	1	2025
Source payment records 2025-06-17 · Phathom Pharmaceuticals, Inc. · $13.11 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	545	130
Amlodipine Besylate	Amlodipine Besylate	386	86
Lisinopril	Lisinopril	365	90
Furosemide	Furosemide	322	92
Metoprolol Succinate	Metoprolol Succinate	301	69
Pantoprazole Sodium	Pantoprazole Sodium	277	71
Levothyroxine Sodium	Levothyroxine Sodium	273	54
Losartan Potassium	Losartan Potassium	241	58
Hydrochlorothiazide	Hydrochlorothiazide	239	56
Pravastatin Sodium	Pravastatin Sodium	231	60
Albuterol Sulfate Hfa	Albuterol Sulfate	226	90
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	188	24
Alprazolam	Alprazolam	182	27
Omeprazole	Omeprazole	182	48
Eliquis	Apixaban	172	30
Prednisone	Prednisone	170	109
Sertraline Hcl	Sertraline Hcl	157	42
Ozempic	Semaglutide	152	20
Potassium Chloride	Potassium Chloride	150	40
Clopidogrel	Clopidogrel Bisulfate	145	42
Lorazepam	Lorazepam	144	37
Metformin Hcl	Metformin Hcl	141	37
Gabapentin	Gabapentin	140	46
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	136	19
Zolpidem Tartrate	Zolpidem Tartrate	133	21
Metoprolol Tartrate	Metoprolol Tartrate	128	30
Tramadol Hcl	Tramadol Hcl	112	35
Azithromycin	Azithromycin	109	94
Hydralazine Hcl	Hydralazine Hcl	109	22
Rosuvastatin Calcium	Rosuvastatin Calcium	104	26
Montelukast Sodium	Montelukast Sodium	102	24
Rybelsus	Semaglutide	99	19
Farxiga	Dapagliflozin Propanediol	96	21
Repatha Sureclick	Evolocumab	89	13
Alendronate Sodium	Alendronate Sodium	88	22
Ezetimibe	Ezetimibe	86	22
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	85	24
Mirtazapine	Mirtazapine	85	19
Trazodone Hcl	Trazodone Hcl	85	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	82	18
Meloxicam	Meloxicam	80	21
Triamcinolone Acetonide	Triamcinolone Acetonide	78	32
Allopurinol	Allopurinol	75	22
Carvedilol	Carvedilol	73	19
Tamsulosin Hcl	Tamsulosin Hcl	70	23
Labetalol Hcl	Labetalol Hcl	69	16
Enalapril Maleate	Enalapril Maleate	68	16
Doxycycline Hyclate	Doxycycline Hyclate	65	58
Simvastatin	Simvastatin	63	11
Memantine Hcl	Memantine Hcl	61	14
Donepezil Hcl	Donepezil Hcl	60	17
Paroxetine Hcl	Paroxetine Hcl	60	14
Nortriptyline Hcl	Nortriptyline Hcl	59	16
Colchicine	Colchicine	57	20
Torsemide	Torsemide	56	20
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	56	14
Duloxetine Hcl	Duloxetine Hcl	55	13
Venlafaxine Hcl Er	Venlafaxine Hcl	53	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	52	32
Fluticasone Propionate	Fluticasone Propionate	51	23
Jardiance	Empagliflozin	50	11
Clonazepam	Clonazepam	49	suppressed
Fenofibrate	Fenofibrate	48	12
Hydroxyzine Hcl	Hydroxyzine Hcl	47	suppressed
Humalog Kwikpen U-100	Insulin Lispro	46	15
Januvia	Sitagliptin Phosphate	46	suppressed
Metformin Hcl Er	Metformin Hcl	43	14
Estradiol	Estradiol	41	15
Ondansetron Hcl	Ondansetron Hcl	40	24
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	40	34
Tizanidine Hcl	Tizanidine Hcl	40	suppressed
Ibuprofen	Ibuprofen	39	17
Nystatin	Nystatin	36	16
Oxycodone Hcl	Oxycodone Hcl	36	suppressed
Famotidine	Famotidine	34	12
Spironolactone	Spironolactone	34	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	32	suppressed
Temazepam	Temazepam	32	suppressed
Bupropion Hcl Sr	Bupropion Hcl	31	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	30	30
Xarelto	Rivaroxaban	30	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	27	12
Sucralfate	Sucralfate	27	suppressed
Warfarin Sodium	Warfarin Sodium	27	suppressed
Atenolol	Atenolol	26	suppressed
Breo Ellipta	Fluticasone/Vilanterol	26	suppressed
Diclofenac Sodium	Diclofenac Sodium	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Levetiracetam	Levetiracetam	26	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Benazepril Hcl	Benazepril Hcl	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Klor-Con M20	Potassium Chloride	25	suppressed
Glipizide	Glipizide	24	suppressed
Incruse Ellipta	Umeclidinium Bromide	24	suppressed
Olanzapine	Olanzapine	24	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	23	suppressed
Propranolol Hcl	Propranolol Hcl	23	suppressed
Sps	Sodium Polystyrene Sulfon/Sorb	23	17
Ventolin Hfa	Albuterol Sulfate	23	suppressed
Oxycontin	Oxycodone Hcl	22	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Tresiba Flextouch U-100	Insulin Degludec	21	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Linzess	Linaclotide	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Phenobarbital	Phenobarbital	20	suppressed
Ramipril	Ramipril	20	suppressed
Arnuity Ellipta	Fluticasone Furoate	19	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Lactulose	Lactulose	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	18	16
Finasteride	Finasteride	18	suppressed
Repatha Syringe	Evolocumab	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Entresto	Sacubitril/Valsartan	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	12
Novolin N Flexpen	Insulin Nph Human Isophane	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Primidone	Primidone	17	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	16	suppressed
Clonidine	Clonidine	16	suppressed
Constulose	Lactulose	16	suppressed
Praluent Pen	Alirocumab	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Valsartan	Valsartan	16	suppressed
Fluconazole	Fluconazole	15	13
Naproxen	Naproxen	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Bumetanide	Bumetanide	14	suppressed
Methotrexate	Methotrexate Sodium	14	suppressed
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Calcitriol	Calcitriol	13	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	13	suppressed
Dilantin	Phenytoin Sodium Extended	13	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Valacyclovir	Valacyclovir Hcl	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Cefdinir	Cefdinir	12	suppressed
Clindamycin Hcl	Clindamycin Hcl	12	11
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Fesoterodine Fumarate Er	Fesoterodine Fumarate	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Pentoxifylline	Pentoxifylline	12	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	12	suppressed
Sotalol	Sotalol Hcl	12	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Carisoprodol	Carisoprodol	11	suppressed
Cefadroxil	Cefadroxil	11	11
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Lacosamide	Lacosamide	11	suppressed
Morphine Sulfate	Morphine Sulfate	11	suppressed
Naltrexone Hcl	Naltrexone Hcl	11	suppressed
Olanzapine Odt	Olanzapine	11	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$60.26 · 3 records	Abbott Laboratories	FREESTYLE LIBRE 3, NEXLETOL, VOQUEZNA	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error